Eli Lilly (LLY) news

Older LLY news events, each with the realized, point-in-time move the market made — page 5 of 8. Back to the LLY overview → · Full LLY reaction history →

Latest news

Recent LLY events, each with its measured reaction. (Page 5 of 8.)

DateHeadlineEventSource5-minTo close
Lilly to participate in Goldman Sachs 46th Annual Global Health Care ConferencePress releasePR Newswire-0.12%+1.81%
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific SessionsPress releasePR Newswire-0.64%+1.75%
Lilly to expand its pain pipeline with acquisition of SiteOne TherapeuticsPress releasePR Newswire+0.38%+0.77%
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual MeetingPress releasePR Newswire+0.72%+0.52%
Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's diseasePress releasePR Newswire-0.40%-0.17%
LILLY CANADA ANNOUNCES AVAILABILITY OF MOUNJARO® KWIKPEN® (TIRZEPATIDE INJECTION) IN ALL DOSES, ADVANCING CARE FOR ADULTS LIVING WITH TYPE 2 DIABETESPress releaseCanada Newswire-1.01%-1.34%
Darkness to Light Receives Grant from Direct Relief's Fund for Health Equity to Advance Prevention WorkPress releasePR Web+1.50%+3.93%
Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of MedicinePress releasePR Newswire+1.50%+3.93%
Form SD ELI LILLY & CoSEC filing · Form SDSEC EDGAR+1.50%+3.93%
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovationPress releasePR Newswire+0.75%-2.32%
Form 8-K ELI LILLY & Co For: May 05SEC filing · Form 8-KSEC EDGAR+0.75%-2.32%
Lilly announces transitions in executive leadershipPress releasePR Newswire-1.76%-1.57%
Lilly declares second-quarter 2025 dividendPress releasePR Newswire+0.17%-0.06%
Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly’s Gene Therapy DivisionPress releaseBusiness Wire+0.24%+0.55%
Lilly to participate in Bank of America Securities 2025 Healthcare ConferencePress releasePR Newswire+0.25%+0.17%
Form 10-Q ELI LILLY & Co For: Mar 31SEC filing · Form 10-QSEC EDGAR-0.23%-2.68%
Form 8-K ELI LILLY & Co For: May 01SEC filing · Form 8-KSEC EDGAR-0.49%-5.91%
Lilly reports first-quarter 2025 financial results and highlights pipeline momentumPress releasePR Newswire-0.49%-5.91%
Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular DisordersPress releaseBusiness Wire+0.21%+0.95%
Lilly confirms date and conference call for first-quarter 2025 financial results announcementPress releasePR Newswire-0.30%-0.71%
Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trialPress releasePR Newswire-0.59%+0.21%
Lilly's Dave Ricks Named Chief Executive Magazine's 2025 CEO of the YearPress releasePR Web-0.51%+3.73%
Kanvas Bio Publishes New Research on its Novel Spectral Imaging Platform, a Transformative Tool for Microbiome Drug Discovery and DevelopmentPress releasePR Newswire+0.14%-1.41%
Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levelsPress releasePR Newswire-1.47%+2.09%
LillyDirect platform expands to facilitate access to Alzheimer's disease carePress releasePR Newswire-0.26%-0.40%
2025 ISPE Biotechnology Conference Announces Keynote SpeakersPress releasePR Web-0.24%-2.24%
Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual MeetingPress releasePR Newswire-0.24%-2.24%
Form DEF 14A ELI LILLY & Co For: Mar 21SEC filing · Form DEFSEC EDGAR+0.08%+2.60%
Form DEFA14A ELI LILLY & CoSEC filing · Form DEFA14ASEC EDGAR+0.08%+2.60%
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS studyPress releasePR Newswire+0.48%-2.57%
Form PRE 14A ELI LILLY & Co For: Mar 07SEC filing · Form PRESEC EDGAR+0.48%-2.57%
Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitisPress releasePR Newswire-0.31%-3.96%
Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDAPress releaseBusiness Wire-1.10%-1.59%
Lilly to participate in Leerink Partners Global Healthcare ConferencePress releasePR Newswire-0.41%+1.79%
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitorPress releasePR Newswire+0.04%+1.54%
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billionPress releasePR Newswire+0.54%+1.67%
Lilly launches additional Zepbound vial doses and offers new savings for self-pay patientsPress releasePR Newswire+1.12%+1.10%
Form 10-K ELI LILLY & Co For: Dec 31SEC filing · Form 10-KSEC EDGAR-0.22%+0.29%
Form S-3ASR ELI LILLY & CoSEC filing · Form S-3ASRSEC EDGAR+0.36%+0.72%
Lilly to participate in TD Cowen's 45th Annual Health Care ConferencePress releasePR Newswire+0.47%+0.05%
Form 8-K ELI LILLY & Co For: Feb 10SEC filing · Form 8-KSEC EDGAR+0.26%-0.28%
2025 ISPE Aseptic Conference in Washington, D.C. Provides In-Depth How-to Information and Insights on New ModalitiesPress releasePR Web+0.09%-0.29%
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two yearsPress releasePR Newswire-0.05%+0.08%
Form 8-K ELI LILLY & Co For: Feb 06SEC filing · Form 8-KSEC EDGAR+3.40%+3.93%
Lilly reports full Q4 2024 financial results and provides 2025 guidancePress releasePR Newswire+3.40%+3.93%
Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcementPress releasePR Newswire+0.30%+2.48%
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel diseasePress releasePR Newswire+0.33%+1.33%
Form 8-K ELI LILLY & Co For: Jan 14SEC filing · Form 8-KSEC EDGAR-1.88%-4.50%
Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidancePress releasePR Newswire-1.88%-4.50%
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Ka inhibitor programPress releasePR Newswire-0.02%+0.60%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground